Geen internetverbinding — de opgeslagen versie van de pagina wordt getoond.

Agios Pharm

USUSD
← Naar de Screener

Agios Pharm (LSE:0HB0) — Biotechnology: Pharmaceutical Preparations. Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 2. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.

Over het Bedrijf

Website
agios.com
Beleggersrelaties
investor.agios.com/
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Hoofdkantoor
Cambridge, United States
CEO
Brian M. Goff
Werknemers
539
Opgericht
2008
Uitstaande Aandelen
59.7 mln. per 2026-07-24
Free Float
50.02 mln.
Marktkapitalisatie
2 mld. USD
Insiders
1.07%
Institutionele Beleggers
112.31%
Branche (SIC)
Pharmaceutical Preparations
ISIN
US00847X1046
LEI
529900ONJHY8EOGYT555
FCF
−365 mln. USD
Schuld
0
Winst en FCF — voor de 12 maanden tot 30.06.2026 (het laatste rapport van het bedrijf).
Beschrijving

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Beurzen en Tickers

BeursTickerValutaPrijsType
US USA StocksAGIO primairUSD31.92 +0.41%gewone aandelen
LSE London Stock Exchange0HB0 IOBUSD33.1105 +0.00%gewone aandelen

Koers over 3 Maanden

stijgingsdag dalingsdagBeweeg over / tik op een dag — openings-, slot-, hoogste en laagste koers
advertentie

Grootste Aandeelhouders

HouderBelangAandelenRapportdatum
Blackrock Inc.10.81%6.46 mln.2026-06-30
Farallon Capital Managem…9.91%5.92 mln.2026-06-30
State Street Corporation5.92%3.53 mln.2026-06-30
Lynx1 Capital Management…5.71%3.41 mln.2026-06-30
Shaw D.E. & Co., Inc.5.2%3.11 mln.2026-06-30
Vanguard Portfolio Manag…4.85%2.9 mln.2026-06-30
Vanguard Capital Managem…4.49%2.68 mln.2026-06-30
Armistice Capital, LLC4.02%2.4 mln.2026-06-30
Erste Asset Management G…3.61%2.15 mln.2026-06-30
SPDR SERIES TRUST-State…3.54%2.11 mln.2026-08-31
Nomura Asset Management…3.54%2.11 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…3.16%1.89 mln.2026-06-30
iShares Trust-iShares Ru…2.52%1.51 mln.2026-07-31
VANGUARD INDEX FUNDS-Van…2.28%1.36 mln.2026-06-30
Delaware Group Equity Fu…1.92%1.14 mln.2026-05-31
VANGUARD INDEX FUNDS-Van…1.32%788 6552026-06-30
VANGUARD INDEX FUNDS-Van…1.15%683 9902026-06-30
Fidelity Salem Street Tr…1.08%646 3182026-07-31
Fidelity Rutland Square…0.88%526 1212026-07-31
iShares Trust-iShares Ru…0.86%511 9942026-07-31
FOUSE JACQUALYN A. (Dire…≈0.26%154 1562026-06-18
GHEUENS SARAH (Officer)≈0.09%54 6452026-08-04
SCADDEN DAVID T. (Direct…≈0.03%20 4192026-06-18
HO MAYKIN (Director)≈0.03%19 8482026-06-18
BALLAL RAHUL D. (Directo…≈0.03%15 2302026-06-18
SMITH CYNTHIA (Director)≈0.03%15 2302026-06-18
FOSTER-CHEEK KAYE I (Dir…≈0.02%12 4842026-06-18
ADAMS CATHERINE OWEN (Di…≈0.02%10 8652026-06-18
CAPELLO JEFFREY D (Direc…≈0.02%10 8652026-06-18
BACKSTROM JAY T (Directo…≈0%1 4472026-07-08